The introduction of anti-EGFR therapy for RAS wildtype CRC, the anti-angiogenic therapy with VEGF antibodies and immune checkpoint inhibitors for microsatellite instable cancers have improved systemic CRC therapy in recent years. Here, EGFR is linked to colorectal carcinoma.